News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abingdon Life Sciences, Inc. Announces Appointment of Charles H. Davis, RAC as Vice-President, Regulatory Science


9/8/2008 10:08:44 AM

CARLSBAD, Calif., Sept. 8 /PRNewswire/ -- Abingdon Life Sciences, Inc. a Drug and Device Development Management Organization (DDMO) announced it has appointed Charles H. Davis, RAC as Vice-President, Regulatory Science. Mr. Davis brings a strong background in global regulatory affairs to Abingdon Life Sciences, Inc.

"We are extremely pleased to welcome Charley to Abingdon as head of our Regulatory Science Department," said Aidan Nuttall, Ph.D., Abingdon's President and COO. "Charley brings a wealth of experience to the company. He is a proven leader and has an extremely successful track record in regulatory affairs. He will certainly be a powerful asset to our clients. In recognition of the ever-changing complexity of global regulatory requirements, our clients need for regulatory intelligence and analysis we have re-named our Regulatory Affairs department to Regulatory Science to more accurately reflect the operations within that department. Charley will be leading that development and we are confident our clients will appreciate the benefits of having him on Abingdon's team," continued Dr. Nuttall. "I am very pleased to be joining the world class team at Abingdon and certainly look forward to being able to contribute to Abingdon and the unique regulatory science challenges of our client companies," said Mr. Davis.

Mr. Davis joins Abingdon from Santarus Pharmaceuticals where he was Senior Director, Regulatory Affairs. Mr. Davis, with over twenty years of regulatory experience, has brought both drug and biologic products to commercial launch in the fields of cardiac imaging, coronary angioplasty, oncology, gastroenterology, parenteral nutrition, ophthalmology and contraception.

About Abingdon Life Sciences, Inc.:

Abingdon Life Sciences, Inc. is a first-in-class Drug and Device Development Management Organization (DDMO) providing drug and device companies superior clinical and regulatory services based on an integrated strategic development model. Abingdon's senior executives provide personalized oversight and leadership of projects to ensure the best possible customer experience.

CONTACT: Aidan Nuttall, Ph.D., of Abingdon Life Sciences, Inc.,
+1-760-268-1078, anuttall@abingdoncorp.com

Web site: http://www.abingdoncorp.com/


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES